Research Analysts’ Weekly Ratings Updates for CryoPort (CYRX)

CryoPort (NASDAQ: CYRX) recently received a number of ratings updates from brokerages and research firms:

• 6/8/2026 – CryoPort was given a new $13.50 price target by Jefferies Financial Group Inc..
• 6/8/2026 – CryoPort had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $13.00 price target on the stock.
• 6/3/2026 – CryoPort had its price target raised by Craig Hallum from $15.00 to $20.00. They now have a “buy” rating on the stock.
• 5/20/2026 – CryoPort had its price target raised by KeyCorp from $15.00 to $17.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – CryoPort was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – CryoPort was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/5/2026 – CryoPort had its price target raised by Guggenheim from $11.00 to $12.00. They now have a “buy” rating on the stock.
• 5/5/2026 – CryoPort had its price target raised by BTIG Research from $15.00 to $17.00. They now have a “buy” rating on the stock.
• 5/5/2026 – CryoPort had its price target raised by Needham & Company LLC from $13.00 to $15.00. They now have a “buy” rating on the stock.
• 5/3/2026 – CryoPort was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/25/2026 – CryoPort was upgraded by Wall Street Zen from “sell” to “hold”.

Insider Buying and Selling at CryoPort

In other news, CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $16.27, for a total value of $2,756,577.29. Following the completion of the transaction, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at approximately $1,787,259.50. The trade was a 60.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jerrell Shelton sold 7,918 shares of CryoPort stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $8.00, for a total transaction of $63,344.00. Following the completion of the transaction, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at $8,436,008. This trade represents a 0.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 252,580 shares of company stock valued at $3,586,185. Corporate insiders own 10.10% of the company’s stock.

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.